SCHEMBL20028271

SCHEMBL20028271

CC(C)n1cnc2c(Nc3cccc(Cl)c3)nc(NC3CCCNC3)nc21

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CLK1 P49759 9/20 0.80
▸ CLK2 P49760 9/20 0.80
▸ CLK4 Q9HAZ1 9/20 0.80
▸ CDK1 P06493 7/20 0.73
▸ CCNB1 P14635 3/20 0.68
▸ CDK4 P11802 2/20 0.68
▸ CCND3 P30281 1/20 0.68
▸ EIF2AK2 P19525 1/20 0.59
▸ GSK3B P49841 1/20 0.59
▸ MERTK Q12866 1/20 0.59
▸ KDM4E B2RXH2 4/20 0.58
▸ CDK5 Q00535 3/20 0.58
▸ CDK5R1 Q15078 3/20 0.58
▸ MAPT P10636 3/20 0.58
▸ MAPK1 P28482 2/20 0.58
▸ CCNE1 P24864 2/20 0.58
▸ CDK2 P24941 2/20 0.58
▸ MEN1 O00255 1/20 0.58
▸ CCNB2 O95067 1/20 0.58
▸ PAK4 O96013 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20027789 1.00 CLK1 (0.80) CLK1CLK2CLK4CDK1CCNB1
SCHEMBL20027791 1.00 CLK1 (0.80) CLK1CLK2CLK4CDK1CCNB1
SCHEMBL20027793 0.95 CLK1 (0.79) CLK1CLK2CLK4CDK1CCNB1
SCHEMBL20027792 0.95 CLK1 (0.79) CLK1CLK2CLK4CDK1CCNB1
SCHEMBL20028201 0.95 CLK1 (0.79) CLK1CLK2CLK4CDK1CCNB1
SCHEMBL21282798 0.91 CLK1 (0.72) CLK1CLK2CLK4CDK1CCNB1
SCHEMBL21282792 0.91 CLK1 (0.71) CLK1CLK2CLK4CDK1CCNB1
SCHEMBL22783739 0.91 CLK1 (0.71) CLK1CLK2CLK4CDK1CCNB1
SCHEMBL20028328 0.89 CLK1 (1.00) CLK1CLK2CLK4CDK1CCNB1
SCHEMBL20027887 0.89 CLK1 (1.00) CLK1CLK2CLK4CDK1CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018064545-A1 DUAL CLK/CDK1 INHIBITORS FOR CANCER TREATMENT SRI INTERNATIONAL (US) 2018-04-05 — — WO disclosed
Send feedback